Colorectal Cancer Therapeutics Market Outlook:
Colorectal Cancer Therapeutics Market size was valued at USD 19.2 billion in 2024 and is projected to reach USD 33.6 billion by the end of 2037, rising at a CAGR of 6.5% during the forecast period, i.e., 2025-2037. In 2025, the industry size of colorectal cancer therapeutics is estimated at USD 20.6 billion.
Key Colorectal Cancer Therapeutics Market Insights Summary:
North America market is projected to account for the largest market share of 42.7% in the colorectal cancer therapeutics market during the forecast period.
Europe is likely to maintain its status as the second-largest contributor in terms of revenue throughout the assessed timeframe.
Asia Pacific is expected to register the fastest growth rate of 8.5% in the colorectal cancer therapeutics market during the projected period.
The metastatic stage is forecasted to secure the highest share of 68.4% in the colorectal cancer therapeutics market by 2037, based on cancer stage.
The targeted therapy segment is anticipated to achieve a substantial share of 52.5% in the market over the forecast timeline.
Key Growth Drivers:
- Critical benefits offered by early interventions
- Vigorous strategies implemented by global giants
Key Players:
- Roche, Merck & Co., Bristol-Myers Squibb, Amgen, Pfizer, Novartis, Sanofi, AstraZeneca, Eli Lilly, Bayer, Johnson & Johnson, GSK (GlaxoSmithKline), Celltrion, Biocon
Market Size and Growth Projections:
- 2024 Market Size: USD 19.2 billion
- 2025 Market Size: USD 20.6 billion
- Projected Market Size: USD 33.6 billion by 2037
- Growth Forecasts: 6.5% CAGR (2025-2037)
- Largest Region: North America
- Fastest Growing Region: North America
The escalating instances of colorectal cancers and associated mortalities across all nations are primary drivers behind the robust growth of the market. As evidence in 2023, the World Health Organization reported that over 1.8 million new colorectal cancer cases are being diagnosed annually, creating a nationwide surge for the therapeutics, whereas the 5-year prevalence is reported to exceed 6.5 million patients. The high-income countries are witnessing this incidence owing to the presence of rising aging demographics and unhealthy lifestyle habits, with North America and Europe together comprising 56% of cases unveiled by the NIH 2024 data.
The supply chain aspect is yet another factor placing positive footprints in the market. It generally involves complex logistics with APIs sourced 35% from India and 20% from China, whereas the finished drug formulations are primarily being manufactured in the U.S., Germany, and Switzerland. On the other hand, the WTO in 2023 reported that medical devices such as liquid biopsy kits and endoscopic tools rely on semiconductor and precision engineering supply chains, with 60% of critical components being imported from Japan and South Korea, thus creating a prolific market opportunity.
Colorectal Cancer Therapeutics Market - Growth Drivers and Challenges
Growth Drivers
- Critical benefits offered by early interventions: With the proven validations offered by reputed organizations, the market displays greater acceptance. Testifying to the same, the AHRQ conducted research and found that early-stage CRC drug interventions efficiently reduced hospitalizations by 23%, thereby saving USD 1.9 billion in the U.S. healthcare expenses within two years. Such evidence and scaling liquid biopsy-based screening in emerging markets is anticipated to replicate the cost savings witnessed in the U.S. and EU.
- Vigorous strategies implemented by global giants: Considering the efficacy and acceptance offered by the market, the global players are implementing continued strategies to facilitate revenue. For instance, in 2024, the U.S. FDA reported that Roche, in partnership with 10 hospitals based in the EU, deployed AI-based CRC technologies, thereby gaining 8.9% in added revenue. Simultaneously, Merck’s Keytruda gained FDA fast-track approval for MSI-H CRC, hence grabbing 30.5% of the U.S. immunotherapy market.
Historical Patient Growth & Its Impact on Market Expansion
The dramatic expansion in terms of patient base in the colorectal cancer therapeutics market over the last decade has embarked on a transformative phase in the upliftment. Aging demographics, improved diagnostic capabilities, and evolving therapeutic procedures progressively influence the market expansion. Particularly, the strike of the U.S. and EU, which account for nearly 60% of the global drug revenue in 2020, reflects the significance of expanded accessibility and reimbursement support. Besides, the divergence with Asia Pacific’s low per capita healthcare spending creates an opportunity for manufacturers to penetrate the emerging markets with affordable biosimilars and domestic production capabilities.
Historical Patient Growth in Key Markets 2010–2020
|
Country |
CRC Patients (2010) |
CRC Patients (2020) |
Key Driver |
|
U.S. |
1.3 million |
1.9 million |
Medicare expansion, screening uptake |
|
Germany |
460,000 |
685,000 |
Universal healthcare, early detection |
|
France |
385,000 |
556,000 |
National Cancer Plan (2014–2019) |
|
Spain |
300,000 |
430,000 |
Rising obesity rates |
|
Australia |
189,000 |
266,000 |
High screening compliance |
|
Japan |
625,000 |
954,000 |
Aging population, precision medicine |
|
India |
354,000 |
785,000 |
Urbanization, processed food consumption |
|
China |
1.2 million |
2.5 million |
Healthcare infrastructure growth |
Feasible Expansion Models Shaping the Future of CRC Therapeutics
The gradual evolution in the colorectal cancer therapeutics market is mainly followed by the business models undertaken by the universal giants. They have successfully implemented models that balance affordability, innovation, and localization. In terms of emerging markets such as India and China, collaborations with public hospitals and biosimilar adoption significantly improved access, whereas developed economies such as the U.S. and EU prioritize precision oncology and immunotherapy, thereby progressing revenue in the sector.
Feasibility Models for CRC Market Expansion
|
Model |
Region |
Revenue Impact (2023–2025) |
|
Biosimilar PPPs |
India |
+13.4% CAGR |
|
Liquid Biopsy Subsidies |
Germany |
+$226 million |
|
API Localization |
China |
-18.7% import costs |
|
Tele-oncology |
Brazil |
+10.4% patient reach |
Challenges
- Regulatory and clinical trial recruitment hurdles: Inefficiency in terms of bureaucratic delays and hurdles in clinical trial recruitment significantly hampers growth in the market. As evidence, Japan’s PMDA delayed the approval by 18 months for clinical data. Whereas in the U.S., 42% of clinical trials fail to enroll minority patients. However, organizations addressed this with domestic trials and the launch of specific trial portals, thereby boosting participation and mitigating these roadblocks.
Colorectal Cancer Therapeutics Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.5% |
|
Base Year Market Size (2024) |
USD 19.2 billion |
|
Forecast Year Market Size (2037) |
USD 19.2 billion |
|
Regional Scope |
|
Colorectal Cancer Therapeutics Market Segmentation:
Cancer Stage Segment Analysis
Based on cancer stage, the metastatic stage is anticipated to garner the highest share of 68.4% in the colorectal cancer therapeutics market by the end of 2037. The dominance of the segment is highly attributable to the concentration of innovative therapies and the substantial cost-burden of late-stage treatment. Besides, the immunotherapies are particularly concentrated in metastatic disease, with checkpoint inhibitors such as pembrolizumab being incorporated in approximately 90% of MSI-H or dMMR metastatic cases, states the U.S. FDA. Hence, this provides a wider segment scope, denoting a positive market outlook.
Therapy Type Segment Analysis
In terms of therapy type, the targeted therapy segment is expected to attain a considerable share of 52.5% in the market during the forecast timeline. Clinical superiority of EGFR inhibitors, in particular patient population is the key factor propelling growth in the segment. As evidence, the NCI notes that EGFR inhibitors such as cetuximab and panitumumab showcased a 46.3% response rate in left-sided colorectal cancers with RAS wild-type mutations, when compared to just 16% to 20% in conventional chemotherapy procedures. Therefore, these findings have made targeted therapy the gold standard for care in biomarker-selected patients.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegment |
|
Type |
|
|
Installation |
|
|
Application |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Colorectal Cancer Therapeutics Market - Regional Analysis
North America Market Insights
The North America market is expected to hold the largest market share of 42.7% during the forecast tenure. The proprietorship of the region is effectively attributable to the accelerated adoption of next-generation therapies, with CAR-T and bispecific antibodies entering late-stage trials for refractory cases. Besides, the region is leading in terms of real-world evidence, with 76% of the oncologists leveraging HER-linked databases to mentor the treatment procedure. In addition, the aspect of value-based contracts currently offering coverage to 32% of insurance plans further solidifies reimbursement to progression-free survival.
The U.S. is steadily augmenting its position in the regional market with the dominance of immunotherapy and liquid biopsy adoption. Testifying to the same, U.S. FDA reported PD-1 inhibitors currently cover 40% of MSI-H and DMMR cases, whereas the CDC notes that 65% of oncologists in the country utilize blood tests for monitoring. Besides, the federal healthcare spending for colorectal cancer therapeutics reached USD 2.9 billion in 2025, and Medicare Part B expenses on biologics grew at 19.4% year-over-year.
Canada's market is poised for growth with the presence of provincial investments from federal and institutional authorities. For instance, in 2024, Health Canada reported the federal allocation surpassed USD 1.2 billion, with Ontario spending 22.7% more on colorectal cancer therapeutics since 2021. Besides the domestic shift towards biosimilars, with 52% of bevacizumab prescriptions are propelling augmentation of the country. Furthermore, the prime focus on indigenous health, with USD 120 million dedicated to CRC screening, evidently drives upliftment.
Europe Market Insights
Europe is estimated to retain its position as the second-largest revenue holder in the colorectal cancer therapeutics market through the assessed timeframe. The region’s standard in upliftment is attributed to precision medicine adoption and nationwide healthcare initiatives. Particularly, the allocation of €2.7 billion for colorectal cancer research by EHDS focuses on biomarker-driven therapies, thus denoting a great opportunity for domestic manufacturers. Besides, in the UK, the NHS’s Rapid Cancer Diagnostic System has significantly reduced late-stage diagnoses by 17.4%.
Germany is prospering in a profitable atmosphere with a dominating share of 32.7% in the regional market. This is propelled by its robust ecosystem in terms of innovation and development. Besides, the National Decade Against Cancer Initiative extended its support by granting €1.3 billion in funding for CAR-T trials, whereas the AMNOG’s value assessments ensure cost-optimization. Furthermore, the EMA proclaimed that 90% of metastatic patients in the country receive biomarker therapy, creating an optimistic manufacturer opportunity.
France is progressing in the market with its exceptional potential to dominate the Europe market. The country is augmenting such growth with the adoption of biosimilars and the progressive developments in AI-based diagnostics. Germany hosts a 2025 cancer plan that allocated €220 million for liquid biopsy rollouts, reflecting a deliberate commitment to serve the patient population. On the other hand, it is reported that 70% of hospitals in the country currently utilize real-world evidence for treatment decisions, enhancing the procedures.
APAC Market Insights
Asia Pacific is anticipated to exhibit the fastest growth rate of 8.5% in the colorectal cancer therapeutics market throughout the assessed timeframe. The vigorous burden of colorectal cancer, improved diagnostics, and government-led healthcare reforms are key factors contributing to the growth of the region. Japan is leading the market with innovations and allocation of 13.6% of its healthcare budget towards colorectal cancer therapeutics. Besides reimbursement reforms for targeted therapies in South Korea and public-private collaborations in Malaysia, fosters appreciable growth on a larger scale.
China is maintaining its regional dominance in the market, grabbing 45.7% of the regional share primarily owing to the disease incidence and government medical expenditure. Testifying to the same, the country reports 1.6 million yearly CRC cases and NMPA notes a 16% spending increase. Besides, the government presents the Healthy China 2030 initiative, allocating USD 2.9 billion to oncology, with 86% of tier-3 hospitals currently offering PD-1 inhibitors. Furthermore, the domestic manufacturers such as Hengrui Pharma control 40% of the domestic production, denoting an intensifying landscape.
India is experiencing robust growth in the market, with an 18.6% increase in the annual spending that reached USD 2.3 billion in 2023. This is highly attributable to the rising urban incidence and improved diagnostics. On the other hand, the shortage of access among the 72% rural population creates a USD 2.4 billion worth of market opportunity for affordable diagnostics and biosimilars. The Ayushman Bharat scheme offers coverage to 50% of chemotherapy expenses, whereas domestic biosimilar production has reduced prices by 60% since 2020, hence suitable for market development.
Country-Wise Government Initiatives
|
Country |
Key Initiative |
Budget (USD) |
Launch Year |
Focus Area |
|
Australia |
Medical Research Future Fund (MRFF) |
$55 million |
2023 |
Immunotherapy clinical trials |
|
Japan |
Cancer Genomic Medicine Project |
$210 million |
2021 |
Personalized cancer therapy |
|
South Korea |
Moonshot Cancer Research Project |
$520 million |
2024 |
CAR-T cell therapy development |
|
Malaysia |
MySalam CRC Treatment Fund |
$25 million |
2022 |
Financial aid for treatment |
Key Colorectal Cancer Therapeutics Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The market hosts an intensifying landscape with giants such as Roche, Merck, and Bristol-Myers Squibb dominating with the presence of immunotherapies and targeted drugs. Besides the U.S. and Europe-based players lead in terms of checkpoint inhibitors, whereas emerging economies such as India and South Korea contribute biosimilars at an affordable cost. Further, the strategic collaborations opted for by Chugai and Roche shape innovation in this sector.
Here is the list of some prominent players in the industry:
|
Company Name |
Country |
Market Share (2024) |
Industry Focus |
|
Roche |
Switzerland |
26.2% |
Leader in Bevacizumab (Avastin) and targeted therapies. |
|
Merck & Co. |
U.S. |
19.3% |
Pembrolizumab (Keytruda) for metastatic CRC. |
|
Bristol-Myers Squibb |
U.S. |
13.1% |
Nivolumab (Opdivo) for immunotherapy. |
|
Amgen |
U.S. |
11.8% |
Panitumumab (Vectibix) and biosimilars. |
|
Pfizer |
U.S. |
10.1% |
Chemotherapy drugs like Capecitabine (Xeloda). |
|
Novartis |
Switzerland |
xx% |
Targeted therapy with Zoledronic Acid (Zometa). |
|
Sanofi |
France |
xx% |
Irinotecan (Camptosar) for chemotherapy. |
|
AstraZeneca |
UK/Sweden |
xx% |
Developing Olaparib (Lynparza) for CRC. |
|
Eli Lilly |
U.S. |
xx% |
Ramucirumab (Cyramza) for advanced CRC. |
|
Bayer |
Germany |
xx% |
Regorafenib (Stivarga) for refractory CRC. |
|
Johnson & Johnson |
U.S. |
xx% |
Exploring immunotherapies for CRC. |
|
GSK (GlaxoSmithKline) |
UK |
xx% |
Researching PARP inhibitors for CRC. |
|
Celltrion |
South Korea |
xx% |
Biosimilars for CRC treatments. |
|
Biocon |
India |
xx% |
Affordable biosimilars in emerging markets. |
Below are the areas covered for each company under the top global manufacturers:
Recent Developments
- In May 2024, Merck announced the U.S. FDA approval for KEYTRUDA as a first-line treatment for metastatic colorectal cancer with microsatellite instability-high (MSI-H) biomarkers.
- In January 2024, Guardant Health introduced Shield, a liquid biopsy test for early CRC detection, achieving 92.6% accuracy in clinical trials. The test reduces diagnostic time from weeks to 48 hours.
Author Credits: Radhika Pawar
- Report ID: 436
- Published Date: Jun 24, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Copyright @ 2025 Research Nester. All Rights Reserved.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
See our insights in action - schedule your demo now!